Autopsy report · NCT01247922

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

“In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, the companion trial, OSI-774-206 has been stopped”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 1 year 4 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 3 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

OSI Pharmaceuticals

Sponsor type

Industry

Conditions

Ependymoma

Interventions

Erlotinib

Participants

4

Sites

21

Countries

Canada, United Kingdom, United States

Trials that died the same way

• Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease
  “As no safety warnings were detected, Interim analysis from the first 40 patients recommends to stop the trial for futility” (66% match in meaning)
• Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
  “The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.” (64% match in meaning)
• A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
  “The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.” (62% match in meaning)
• A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
  “Due to safety findings in ongoing Phase 2 trials.” (61% match in meaning)
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  “Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.